About Collegium Pharmaceutical Inc.

Collegium Pharmaceutical Inc. was founded in 2002 with a mission to develop abuse-deterrent opioid formulations and pain management therapies. The company has built expertise in drug formulation technologies, particularly in developing products that help address the opioid crisis while providing effective pain relief for patients who need it. Collegium's lead product, Xtampza ER, is an abuse-deterrent extended-release oxycodone formulation that represents a significant portion of the company's revenue. The pharmaceutical industry's focus on addressing opioid abuse while maintaining effective pain management solutions directly impacts COLL stock price as investors evaluate the company's market position and growth prospects.

The company is led by CEO Joe Ciaffoni, who has extensive experience in pharmaceutical commercialization and has guided Collegium through its transition from a development-stage company to a commercial-stage pharmaceutical company. The management team includes experienced professionals in drug development, regulatory affairs, and commercial operations who have successfully navigated the complex pharmaceutical regulatory environment. Their strategic decisions regarding product development, commercialization strategies, and market access significantly influence investor confidence and COLL stock price performance in the competitive pharmaceutical sector.

Collegium Pharmaceutical operates in the specialty pharmaceutical market, focusing on central nervous system disorders and pain management. The company generates revenue primarily through the commercialization of Xtampza ER and other pain management products, working with healthcare providers, payers, and patients to ensure appropriate access to their therapies. With ongoing research and development efforts in abuse-deterrent formulations and other pain management solutions, the company continues to invest in innovation while managing the commercial aspects of its current product portfolio. For investors, understanding pharmaceutical market dynamics, regulatory requirements, and the evolving landscape of pain management is important when evaluating Collegium's growth potential and factors affecting its stock price performance.